Early BB-301 gene therapy data show durable swallowing gains and benign safety in OPMD dysphagia, hinting at disease modification.
Jerel A. Banks, MD, PhD
Advertisement
The chief executive officer and chairman of the board of Benitec Biopharma
Articles by Jerel A. Banks, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Expanding Role of Blood-Based Biomarkers in Alzheimer Disease
2
Beyond AAV: How Extracellular Vesicles Are Opening a New Chapter in Duchenne Gene Therapy
3
Advances in Fragile X Syndrome Therapeutics: Overviewing the Pipeline
4
The Role of Cerebrospinal Fluid in Personalized Alzheimer Disease Care: Betty Tijms, PhD
5